| Literature DB >> 30022629 |
Zheng Feng1,2, Hao Wen1,2, Zhaoxia Jiang2,3, Shuai Liu2,4,5,6, Xingzhu Ju1,2, Xiaojun Chen1,2, Lingfang Xia1,2, Junyan Xu2,4,5,6, Rui Bi2,7, Xiaohua Wu1,8.
Abstract
OBJECTIVE: To present the surgical outcomes of advanced epithelial ovarian cancer (AEOC) since the implementation of a personalized approach and to validate multiple predictive models for R0 resection.Entities:
Keywords: No Residual Disease; Perioperative Complications; Predictive Model; R0 Resection; Scoring Method; Surgical Outcomes
Mesh:
Year: 2018 PMID: 30022629 PMCID: PMC6078898 DOI: 10.3802/jgo.2018.29.e65
Source DB: PubMed Journal: J Gynecol Oncol ISSN: 2005-0380 Impact factor: 4.401
Fig. 1Flow diagram for primary treatment of AEOC by specialized ovarian cancer unit at FUSCC (2015.9–2017.8). Group A: PDS; Group B: NAC+IDS; Group C: LP+PDS; Group D: LP+NAC+IDS.
AEOC, advanced epithelial ovarian cancer; FUSCC, Fudan University Shanghai Cancer Center; IDS, interval debulking surgery; LP, laparoscopy; NAC, neoadjuvant chemotherapy; PCI, peritoneal cancer index; PDS, primary debulking surgery; PIV, predictive index value.
Patient characteristics (n=161)
| Characteristics | Value | |
|---|---|---|
| Age | 57 (27–77) | |
| FIGO stage | ||
| Early | 3 (1.9) | |
| Advanced | 158 (98.1) | |
| Stage III | 128 (79.5) | |
| Stage IV | 30 (18.6) | |
| Family history | ||
| Yes | 54 (33.5) | |
| No | 107 (66.5) | |
| CA-125 (IU/mL) | 1,062 (39.19→5,000) | |
| Radiological score | 4 (0–12) | |
| Histology | ||
| High-grade serous | 131 (81.4) | |
| Low-grade serous | 4 (2.5) | |
| Endometrioid | 1 (0.6) | |
| Clear cell | 6 (3.7) | |
| Carcinosarcoma | 1 (0.6) | |
| Undifferentiated | 11 (6.8) | |
| Regression | 7 (4.3) | |
Values are presented as median (range) or number (%).
CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.
Patient characteristics and surgical variables according to the stratification groups
| Parameters | Group A | Group B | Group C | Group D | |
|---|---|---|---|---|---|
| No. of patients | 77 | 43 | 33 | 8 | |
| Radiological score | 2 (0–7) | 6 (3–12) | 5 (0–10) | 6 (3–9) | |
| Eisenkop | 7 (1–14) | 6 (0–12) | 9 (0–12) | 8 (2–11) | |
| PCI | 13 (2–31) | 11 (0–22) | 18 (3–30) | 13 (4–24) | |
| Aletti | |||||
| Low (0–3) | 15 (19.5) | 18 (41.9) | 3 (9.1) | 3 (37.5) | |
| Intermediate (4–7) | 22 (28.6) | 6 (14.0) | 15 (45.5) | 1 (12.5) | |
| High (≥8) | 40 (51.9) | 19 (44.2) | 15 (45.5) | 4 (50.0) | |
| Residual disease | |||||
| R0 | 42 (54.5) | 26 (60.5) | 20 (60.6) | 5 (62.5) | |
| R1 | 21 (27.3) | 13 (30.2) | 10 (30.3) | 2 (25.0) | |
| R2 | 14 (18.2) | 4 (9.3) | 3 (9.1) | 1 (12.5) | |
Values are presented as median (range) or number (%). Group A: PDS; Group B: NAC+IDS; Group C: LP+PDS; Group D: LP+NAC+IDS.
IDS, interval debulking surgery; LP, laparoscopy; NAC, neoadjuvant chemotherapy; PCI, peritoneal cancer index; PDS, primary debulking surgery.
Fig. 2Discriminatory power of radiological and intraoperative scores for complete resection.
AUC, area under the curve; CI, confidence interval; PCI, peritoneal cancer index; ROC, receiver operating characteristics.
Fig. 3ROC curve analysis for S-LPS score.
AUC, area under the curve; CI, confidence interval; ROC, receiver operating characteristics; S-LPS, staging laparoscopy.
Surgical results stratified by PDS and NAC groups
| Parameters | PDS | NAC+IDS | p | |
|---|---|---|---|---|
| Group A+C | Group B+D | |||
| No. of patients | 110 | 51 | ||
| Residual disease | 0.622 | |||
| R0 | 62 (56.4) | 31 (60.8) | ||
| R1 | 31 (28.2) | 15 (29.4) | ||
| R2 | 17 (15.5) | 5 (9.8) | ||
| Aletti | 0.001 | |||
| Low (0–3) | 18 (16.4) | 21 (41.2) | ||
| Intermediate (4–7) | 55 (50.0) | 23 (45.1) | ||
| High (≥8) | 37 (33.6) | 7 (13.7) | ||
| Operative time (min) | 202 (83–454) | 166 (72–316) | 0.019 | |
| Intraoperative complication | 0.506 | |||
| No | 102 (92.7) | 49 (96.1) | ||
| Yes | 8 (7.3) | 2 (3.9) | ||
| Postoperative complication | 0.013 | |||
| No | 74 (67.3) | 44 (86.3) | ||
| Yes | 36 (32.7) | 7 (13.7) | ||
| Postoperative stay (day) | 12 (6–61) | 8 (6–24) | <0.001 | |
Values are presented as median (range) or number (%). Complications were classified according to the Clavien-Dindo Classification. Group A: PDS; Group B: NAC+IDS; Group C: LP+PDS; Group D: LP+NAC+IDS.
IDS, interval debulking surgery; LP, laparoscopy; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.